1,551
Views
17
CrossRef citations to date
0
Altmetric
Original Articles

Dosimetric rationale and early experience at UFPTI of thoracic proton therapy and chemotherapy in limited-stage small cell lung cancer

, , , , , , , , & show all
Pages 506-513 | Received 30 Oct 2012, Accepted 18 Jan 2013, Published online: 26 Feb 2013

References

  • Stahel R, Ginsberg R, Havemann K, Hirsch FR, Ihde DC, Jassem J. Staging and prognostic factors in small cell lung cancer: A consensus report. Lung Cancer 1989;5:119–26.
  • De Ruysscher D, Pijls-Johannesma M, Vansteenkiste J, Kester A, Rutten I, Lambin P. Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer. Ann Oncol 2006;17:543–52.
  • Fried DB, Morris DE, Poole C, Rosenman JG, Halle JS, Detterbeck FC, . Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol 2004;22:4837–45.
  • Huncharek M, McGarry R. A meta-analysis of the timing of chest irradiation in the combined modality treatment of limited-stage small cell lung cancer. Oncologist 2004;9: 665–72.
  • Baka S, Califano R, Ferraldeschi R, Aschroft L, Thatcher N, Taylor P, . Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer. Br J Cancer 2008; 99:442–7.
  • Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: A randomized study. J Clin Oncol 1997;15: 893–900.
  • Takada M, Fukuoka M, Kawahara M, Sugiura T, Yokoyama A, Yokota S, . Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: Results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 2002;20:3054–60.
  • Turrisi AT, 3rd, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, . Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. New Engl J Med 1999;340:265–71.
  • Bonner JA, Sloan JA, Shanahan TG, Brooks BJ, Marks RS, Krook JE, . Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma. J Clin Oncol 1999;17:2681–91.
  • Grutters JP, Kessels AG, Pijls-Johannesma M, De Ruysscher D, Joore MA, Lambin P. Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: A meta-analysis. Radiother Oncol 2010;95:32–40.
  • Nakayama H, Sugahara S, Tokita M, Satoh H, Tsuboi K, Ishikawa S, . Proton beam therapy for patients with medically inoperable stage I non-small-cell lung cancer at the university of tsukuba. Int J Radiat Oncol Biol Phys 2010;78:467–71.
  • Chang JY, Zhang X, Wang X, Kang Y, Riley B, Bilton S, . Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2006;65:1087–96.
  • Nichols RCJ, Huh SH, Henderson RH, Zuofeng L, Flampouri S, D’Agostino HJ, . Selective nodal irradiation of regionally advanced non-small-cell lung cancer with proton therapy and IMRT: A dosimetric comparison. Thorac Cancer 2012;3:169–74.
  • Oshiro Y, Mizumoto M, Okumura T, Hashimoto T, Fukumitsu N, Ohkawa A, . Results of proton beam therapy without concurrent chemotherapy for patients with unresectable stage III non-small cell lung cancer. J Thorac Oncol 2012;7:370–5.
  • Hoppe BS, Flampouri S, Henderson RH, Pham D, Bajwa AA, D’Agostino H, . Proton therapy with concurrent chemotherapy for non-small-cell lung cancer: Technique and early results. Clin Lung Cancer 2012;13: 352–8.
  • Chang JY, Komaki R, Lu C, Wen HY, Allen PK, Tsao A, . Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. Cancer 2011;117:4707–13.
  • TNM staging for lung cancer. AJCC Cancer Staging Manual, 7th ed. Chicago, IL: Springer; 2010.
  • Yeung AR, Li J, Shi W, Newlin H, Morris CG, Samant S, . Optimal image-guidance scenario with cone- beam computed tomography in conventionally fractionated radiotherapy for lung tumors. Am J Clin Oncol 2010;33: 276–80.
  • Kang Y, Zhang X, Chang JY, Wang H, Wei X, Liao Z, . 4D Proton treatment planning strategy for mobile lung tumors. Int J Radiat Oncol Biol Phys 2007;67:906–14.
  • De Ruysscher D, Bremer RH, Koppe F, Wanders S, van Haren E, Hochstenbag M, . Omission of elective node irradiation on basis of CT-scans in patients with limited disease small cell lung cancer: A phase II trial. Radiother Oncol 2006;80:307–12.
  • Baas P, Belderbos JS, Senan S, Kwa HB, van Bochove A, van Tinteren H, . Concurrent chemotherapy (carboplatin, paclitaxel, etoposide) and involved-field radiotherapy in limited stage small cell lung cancer: A Dutch multicenter phase II study. Br J Cancer 2006;94:625–30.
  • van Loon J, De Ruysscher D, Wanders R, Boersma L, Simons J, Oellers M, . Selective nodal irradiation on basis of (18)FDG-PET scans in limited-disease small-cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys 2010;77: 329–36.
  • Shirvani SM, Komaki R, Heymach JV, Fossella FV, Chang JY. Positron emission tomography/computed tomography-guided intensity-modulated radiotherapy for limited- stage small-cell lung cancer. Int J Radiat Oncol Biol Phys 2012;82:e91–7.
  • Colaco R, Sheikh H, Lorigan P, Blackhall F, Hulse P, Califano R, . Omitting elective nodal irradiation during thoracic irradiation in limited-stage small cell lung cancer – evidence from a phase II trial. Lung Cancer 2012;76:72–7.
  • Liao Z, Lin SH, Cox JD. Status of particle therapy for lung cancer. Acta Oncol 2011;50:745–56.
  • Giroux Leprieur E, Fernandez D, Chatellier G, Klotz S, Giraud P, Durdux C. Non-small cell lung cancer: Risk factors of radiation pneumonitis. Cancer Radiother 2012;16: 257–62.
  • Gomez DR, Tucker SL, Martel MK, Mohan R, Balter PA, Lopez Guerra JL, . Predictors of high-grade esophagitis after definitive three-dimensional conformal therapy, intensity-modulated therapy, or proton beam therapy for non-small cell lung cancer. Int J Rad Oncol Biol Phys 2012;84: 1010–6.
  • Kalemkerian GP, Akerley W, Bogner P, Borghaei H, Chow LQ, Downey RJ, . Small cell lung cancer. JNCCN 2013;11:78–98.
  • Nichols RC, Huh SN, Henderson RH, Mendenhall NP, Flampouri S, Li Z, . Proton radiation therapy offers reduced normal lung and bone marrow exposure for patients receiving dose-escalated radiation therapy for unresectable stage III non-small-cell lung cancer: a dosimetric study. Clin Lung Cancer 2011;12:252–7.
  • Nichols RC, Huh SH, Hoppe BS, Henderson RH, Li Z, Flampouri S, . Protons safely allow coverage of high-risk nodes for patients with regionally advanced non-small-cell lung cancer. Technol Cancer Res Treat 2011;10:317–22.
  • Nichols RC, Henderson RH, Huh S, Flampouri S, Zuofeng L, Bajwa AA, . Proton therapy for lung cancer. Thorac Cancer 2012;3:109–16.